Clinical Trial Update: Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE) [Phase 4]

View source ↗

Summary

Phase 4 study evaluating Cubicin with and without combination therapy for Staphylococcus aureus infective endocarditis; study terminated with results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infective Endocarditis

Drugs mentioned

• Cubicin (daptomycin)

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Infective Endocarditis | Phase 4 | Status: TERMINATED | Results posted: 2013-05-22